Loading stock data…
$9.49+0.05 (+0.53%)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Pharming Group N.V. in the Healthcare sector is trading at $9.49 with a market capitalization of $775M. Wall Street consensus targets $34.35 (4 analysts), implying a +262.0% move over the next 12 months. The stock is currently near its 52-week low of $9.32, remaining 33.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $90.21M↑ | $72.45M↓ | $106.50M↑ | $97.29M↑ | $93.22M |
| Gross Profit | $75.67M↑ | $65.80M↓ | $85.40M↓ | $90.22M↑ | $84.25M |
| Operating Income | -$111,000↑ | -$5.29M↓ | $2.00M↓ | $15.75M↑ | $9.00M |
| Net Income | $1.64M↑ | -$5.21M↓ | $5.30M↓ | $7.55M↑ | $4.69M |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RU...